Brief: Oramed Announces Top-Line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes
12/01/2023 01:02
Jan 11 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 TRIAL OF
ORMD-0801 FOR THE TREATMENT OF TYPE 2 DIABETES
* ORA-D-013-1 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT
* THERE WERE NO SERIOUS DRUG-RELATED ADVERSE EVENTS
* EXPECTS TO DISCONTINUE ITS ORAL INSULIN CLINICAL
ACTIVITIES FOR
T2D
* THE TRIAL ALSO DID NOT MEET ITS SECONDARY ENDPOINT
Source text for Eikon: ID:nPn9TYspBa
Further company coverage: ORMP.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results